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Delays in immune recovery after allo-HSCT are associated with
increased risks of infection and relapse. Strategies to enhance T-cell
reconstitution could therefore decrease morbidity and mortality.
Interleukin-7 (IL-7) has a central role in T cell development and
survival. Murine models of allo-HSCT have shown that IL-7 en-
hances thymopoiesis and peripheral T cell survival and expansion.
Initial trials with recombinant human IL-7 (rhIL-7) have demon-
strated a dose-dependent expansion of CD41 and CD81 T cells
in patients with solid tumors or HIV infection. Hence we are
conducting a phase I trial of rhIL-7 (CYT107, Cytheris Inc) in re-
cipients of a TCD allo-HSCT. To date, 10 patients (AML 5 7,
MDS 5 2, CML 5 1; median age 5 57.3, range 27-67) have been
treated with escalating doses of rhIL-7 (3 at 10mcg/kg, 6 at
20mcg/kg, 1 at 30mcg/kg - accrual ongoing) administered SQ
weekly for 3 weeks, starting at a median of 86 (range 60-244)
days post HSCT. Toxicities included grade 2 hypersensitivity
drug rash (n5 3) and grade 2 fever (n5 1). A patient with rash after
the 1st injection (20 mcg/kg level) was removed from the study
(evaluable for toxicity only). No patients have developed GVHD,
anti-IL-7 antibodies or neutralizing antibodies. Two patients
with high-risk AML have relapsed (4 and 9 months post rhIL-7),
an incidence consistent with published data in patients undergoing
allo-HSCT for AML in CR. Nine patients remain alive with a me-
dian follow-up of 14.7 months post rhIL-7. At baseline, the median
T cell counts were 85/mm3 (5-272/mm3), 65/mm3 (9-299/mm3)
and 0 (0-17/mm3) for CD41, CD81 and CD45RA1 T cells, re-
spectively. Immune monitoring after rhIL-7 in 8 evaluable patients
has demonstrated an increase in CD41 T cells (na€ıve or central
memory, 69% median increase at day 21 - range 8%-35-fold in-
crease) and CD81 T cells (na€ıve or effector memory, 94% median
increase at day 28 - range 0-11-fold increase). There was no effect
on CD41CD251FoxP31 T cells or B cells. Increased TCR
excision circles (TRECs) were noted in the 5/6 patients analyzed
indicating enhanced T cell production. Finally, all 3 CMV-sero-
positive patients developed CD81T cell CMV-specific responses,
including a patient with prior CMV viremia and low-level CMV-
specific CD81 T cells prior to rhIL-7 (5.3-fold increase to the
A0201-restricted NLV peptide). Our pre-clinical data and early
clinical results suggest that rhIL-7 enhances immune recovery in
recipients of a TCD allo-HSCT without causing GVHD.218
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Viral infections cause morbidity and mortality in allogeneic
HSCT recipients. As an effective treatment option, we and others
have successfully infused in vitro expanded cytotoxic T-cell lines
(CTLs) directed against EBV, CMV and Adv. Human herpes virus
type 6B (HHV6B) is detected in . 50% of HSCT recipients and
associated with severe clinical symptoms including pneumonia, en-
cephalitis, acute GvHD, bone marrow suppression and increased
overall mortality. Production of CTLs to this virus has been
hindered by lack of information regarding immunogenic/protective
target antigens.
To identify immunodominant T cell targets in HHV6, we as-
sessed the cellular immune response directed against 5 HHV6Bantigens (U71, U90, U11, U14 and U54), whose counterparts in
the significantly homologous CMV or HHV7 viruses were found
to be immunogenic. For T cell stimulation we isolated PBMCs
from HHV6 sero1ve, CMV sero-ve donors (thus eliminating
the possibility of cross-reactive T cell recognition), pulsed them
with peptide libraries spanning each antigen, and then expanded
them in vitro in the presence IL-4 and IL-7 for 10 days. The re-
sulting CTLs were predominantly CD41 (mean 62%1/-6%)
with specificity for all stimulating antigens. Using IFNg ELIspot
we were able to identify a hierarchy of immunodominance. In 3
donors, we found that all donors responded to all 5 antigens,
but the magnitude of the response differed. The frequency of T
cells reactive against U90 was 216 median SFC/2x105, range
114-804, followed by U11 (median 196, range 70-202), U14 (me-
dian 165, range 134-237), U54 (median 126, range 51-248) and
U71 (median 47 SFC, range 12-50). To confirm that our chosen
antigens are relevant targets for future immunotherapy studies we
next assessed whether the same profile of specificity was generated
using PBMC as stimulator cells that were infected with the
HHV6B Z29 wild type virus, which has a natural tropism for an-
tigen presenting monocytes and CD4 T cells. On day 10 the ex-
panded T cells were specific for U90 (5/5 donors), U54 (4/5) and
U14, U11 (3/5) and U71 (1/5), with a similar frequency of reactive
cells as using peptide stimulation.
In summary we were able to generate and characterize T cell im-
munity to 5HHV-6B antigens in healthy seropositive donors. These
antigens can now be used to further characterize endogenous T cell
recovery in patients after allogenic stem cell transplantation and to
generate HHV-6B specific CTL for adoptive transfer.219
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Background: Cytomegalovirus (CMV) is an immunmodulatory
herpes virus that significantly contributes to morbidity of allogeneic
stem cell transplant (SCT) recipients. Risk factors for early CMV re-
activation include recipient serostatus, use of total body irradiation,
older age, graft versus host disease (GVHD) and matched unrelated
donor (MUD) transplants. The impact of CMV seropositve donor
status on the incidence and outcome of CMV infection in a seropos-
itive recipient is widely debated. In this study we have identified risk
factors for CMV infection in our patient population and evaluated
the impact of donor serostatus on the incidence and outcome of
CMV infection.
Methods:One hundred and eighty-five consecutive allogeneic SCT
recipients at Moore’s Cancer Center, University of California San
Diego from January 2005-August 2009 were identified and charts
retrospectively reviewed.
Results: Sixty percent (112/185) of SCT’s were related with 40%
(73/185) being matched unrelated donor (MUD). An equal amount
of related and MUD were myeloablative (60%) and non-myelobla-
tive (40%) respectively. The incidence of CMV infection (reactiva-
tion) was 39.5% (73 patients) with 82% (60 patients) reactivating
early (before day 100) at a median day 134 post transplant.
CMV disease developed in 8.1%. CMV seropositve recipients
and Asian Pacific race were significantly associated with CMV in-
fection in multivariate analysis with an OR of 9.15 (95% CI 3.55,
23.63) and 6.20 (95% CI 1.24, 31.03) respectively. CMV seroneg-
ative donor/ seropositive recipient (D-/R1) status was significantly
associated with multiple reactivations ($ 3, p\ .0041), high grade
CMV viremia (p.0286) and increased length of CMV viremia
(p.0038) as compared to CMV seropositive donor/seropositive re-
cipients (D1/R1). Neither CMV reactivation nor donor/recipient
serostatus statistically affected survival at 100 or 365 days post
transplant.
Conclusion: Patients with CMV D1/R1 transplants that went on
to develop CMV infection had improved virus control compared
to CMV (D-/R1) SCT as measured by multiple reactivations,
peak viremia and length of viremia. Donor CMV serostatus should
